Loading
Accession Therapeutics makes modified cold viruses that are designed to enter only cancer cells and deliver an immune-stimulating treatment inside the tumour. Its first product, ATTR-01, is in an early trial in solid tumours.
Accession Therapeutics Limited is an Oxford, UK, company led by chief executive Bent Jakobsen, who previously gave scientific direction to the T cell receptor companies Immunocore and Adaptimmune. Its TROCEPT platform engineers a 'stealth' virus with a viral point of entry intended to target cancer cells while bypassing healthy cells, and uses it to deliver immunotherapy payloads into tumours. The lead candidate TROCEPT-01 (ATTR-01) is given intravenously; TROCEPT-02 (ATTR-02) is the second programme. In December 2025 the company announced it had raised 30.5 million pounds (40 million US dollars) from existing investors to complete the phase 1 data for ATTR-01 and take ATTR-02 into the clinic. Its first registered cancer trial, the ATTEST master protocol NCT06977737, a phase 1/2 study of intravenous ATTR-01 in selected epithelial solid tumours at sites in Spain and the UK, was posted on ClinicalTrials.gov in May 2025.
Investors not recorded; see the round sources.
| Round | Year | Amount | Source |
|---|---|---|---|
| Financing · Announced 4 December 2025 as 30.5 million pounds (40 million US dollars, as stated by the company) from existing investors. | 2025 | $40M | accessiontherapeutics.com |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/